Nature Communications (Nov 2019)
Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma
- Dan Su,
- Dadong Zhang,
- Jiaoyue Jin,
- Lisha Ying,
- Miao Han,
- Kaiyan Chen,
- Bin Li,
- Junzhou Wu,
- Zhenghua Xie,
- Fanrong Zhang,
- Yihui Lin,
- Guoping Cheng,
- Jing-Yu Li,
- Minran Huang,
- Jinchao Wang,
- Kailai Wang,
- Jianjun Zhang,
- Fugen Li,
- Lei Xiong,
- Andrew Futreal,
- Weimin Mao
Affiliations
- Dan Su
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences
- Dadong Zhang
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Jiaoyue Jin
- Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences
- Lisha Ying
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences
- Miao Han
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Kaiyan Chen
- Department of Chemotherapy, Cancer Hospital of the University of Chinese Academy of Sciences
- Bin Li
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Junzhou Wu
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences
- Zhenghua Xie
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Fanrong Zhang
- Department of Breast Surgery, Cancer Hospital of the University of Chinese Academy of Sciences
- Yihui Lin
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Guoping Cheng
- Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences
- Jing-Yu Li
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Minran Huang
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences
- Jinchao Wang
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Kailai Wang
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences
- Jianjun Zhang
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center
- Fugen Li
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Lei Xiong
- Research and Development Institute of Precision Medicine, 3D Medicines Inc.
- Andrew Futreal
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center
- Weimin Mao
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences
- DOI
- https://doi.org/10.1038/s41467-019-12846-7
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Predicting the drug response of patients with cancer is crucial for implementing targeted therapy. Here, Su et al. make patient-derived cell lines and perform targeted sequencing and RNA-seq to identify CDKN2A/2B loss as a predictor of response to CDK4/6 inhibitors in esophageal squamous cell carcinoma.
